Focus Stocks

Hewlett Packard (HPQ)

Hewlett Packard (HPQ)


Dell (DELL)

Dell (DELL)


Facebook (FB)

Facebook (FB)


Apple (AAPL)

Apple (AAPL)


Goldman Sachs (GS)

Goldman Sachs (GS)


Featured Stories

Fred's First Quarter 2012 EPS Increase 17%

Fred's First Quarter 2012 EPS Increase 17%


Newell Rubbermaid to Reaffirm Fiscal Year 2012 Outlook

Newell Rubbermaid to Reaffirm Fiscal Year 2012 Outlook


Best ETFs For Facebook Exposure

Best ETFs For Facebook Exposure


McDonald's Announces Quarterly Cash Dividend

McDonald's Announces Quarterly Cash Dividend


Is KB HOME Closing in to Resistance?

Is KB HOME Closing in to Resistance?


Cerus to Release Fourth Quarter and Year-End 2011 Results on February 28, 2012

CONCORD, Calif.-( Business Wire )-

Cerus Corporation (NASDAQ:CERS) announced today that its fourth quarter and year-end 2011 financial results will be released on Tuesday, February 28, 2012, after the close of the stock market. The company will host a conference call and webcast at 4:15 PM ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.

To access the live webcast, please visit the Investor Relations page of the Cerus web site at http://investor.cerus.com. Alternatively, you may access the live conference call by dialing 866-235-9006 (U.S.) or 631-291-4549 (international).

A replay will be available on the company’s web site, or by dialing 855-859-2056 (U.S.) or 404-537-3406 (international) and entering conference ID number 47235284. The replay will be available approximately three hours after the call through March 13, 2012.

ABOUT CERUS

Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action enables INTERCEPT treatment to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in Europe, Russia, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development. See http://www.cerus.com for more information.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

Cerus CorporationKevin D. Green, 925-288-6138Vice President, Finance & CAO

TradersHuddle Search

Sponsored By:

Stock Search:


Site Search:

Loading

Stock Market

Loading
Chart
o Dow Jones 12,529.75 ▲33.60 (0.27%)
o S&P 500 1,320.68 ▲1.82 (0.14%)
o NASDAQ 2,839.38 ▼10.74 (-0.38%)
INDEXDJX:.DJI

Dow Jones

Company ID [INDEXDJX:.DJI] Last trade:12,529.75 Trade time:4:05PM EDT Value change:▲33.60 (0.27%)
INDEXSP:.INX

S&P 500

Company ID [INDEXSP:.INX] Last trade:1,320.68 Trade time:4:32PM EDT Value change:▲1.82 (0.14%)
INDEXNASDAQ:.IXIC

NASDAQ

Company ID [INDEXNASDAQ:.IXIC] Last trade:2,839.38 Trade time:5:16PM EDT Value change:▼10.74 (-0.38%)
Copyright © 2011 TradersHuddle.com. All Rights Reserved.